302 related articles for article (PubMed ID: 16282339)
1. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
Boeckh M; Kim HW; Flowers ME; Meyers JD; Bowden RA
Blood; 2006 Mar; 107(5):1800-5. PubMed ID: 16282339
[TBL] [Abstract][Full Text] [Related]
2. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
[TBL] [Abstract][Full Text] [Related]
3. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
4. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
5. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
[TBL] [Abstract][Full Text] [Related]
8. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
[TBL] [Abstract][Full Text] [Related]
10. [Serologic follow-up of cytomegalovirus, herpes simplex and varicella-zoster infections in kidney transplant recipients].
Merlino C
G Batteriol Virol Immunol; 1991; 84(1-12):41-52. PubMed ID: 1668971
[TBL] [Abstract][Full Text] [Related]
11. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients.
Lee YJ; Neofytos D; Kim SJ; Cheteyan L; Huang YT; Papadopoulos EB; Jakubowski AA; Papanicolaou GA
Transpl Infect Dis; 2018 Dec; 20(6):e12977. PubMed ID: 30120866
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
Kim DH; Kumar D; Messner HA; Minden M; Gupta V; Kuruvilla J; Chae YS; Sohn SK; Lipton JH
Clin Transplant; 2008; 22(6):770-9. PubMed ID: 18707605
[TBL] [Abstract][Full Text] [Related]
14. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.
Han SB; Kim SK; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH
Medicine (Baltimore); 2017 Apr; 96(14):e6546. PubMed ID: 28383421
[TBL] [Abstract][Full Text] [Related]
15. Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic Cell Transplantation Recipients on Standard Acyclovir Prophylaxis.
Baumrin E; Cheng MP; Kanjilal S; Ho VT; Issa NC; Baden LR
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1642-1647. PubMed ID: 31004745
[TBL] [Abstract][Full Text] [Related]
16. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
[TBL] [Abstract][Full Text] [Related]
17. Antigen-specific T-lymphocyte function after cord blood transplantation.
Cohen G; Carter SL; Weinberg KI; Masinsin B; Guinan E; Kurtzberg J; Wagner JE; Kernan NA; Parkman R
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1335-42. PubMed ID: 17162216
[TBL] [Abstract][Full Text] [Related]
18. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.
Koc Y; Miller KB; Schenkein DP; Griffith J; Akhtar M; DesJardin J; Snydman DR
Biol Blood Marrow Transplant; 2000; 6(1):44-9. PubMed ID: 10707998
[TBL] [Abstract][Full Text] [Related]
19. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.
Pollack M; Heugel J; Xie H; Leisenring W; Storek J; Young JA; Kukreja M; Gress R; Tomblyn M; Boeckh M
Biol Blood Marrow Transplant; 2011 May; 17(5):664-73. PubMed ID: 20699126
[TBL] [Abstract][Full Text] [Related]
20. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation.
Kawamura K; Hayakawa J; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Hematol; 2015 Aug; 102(2):230-7. PubMed ID: 25990803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]